# Cardio Diagnostics Holdings, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Cardio Diagnostics Holdings, Inc.).

## Overview

Cardio Diagnostics Holdings, Inc. develops and commercializes AI-driven DNA biomarker tests for cardiovascular disease. Its core products, Epi+Gen CHD and PrecisionCHD, are designed to help assess coronary heart disease risk and support diagnosis and management of disease. The company was formed around technology invented at the University of Iowa and is building a business around clinical adoption through providers, channel partners, and employers. It operates as an early-stage diagnostic company with a single operating segment focused on product testing and a business model that depends on expanding test utilization and reimbursement acceptance.

## Products & services

• Epi+Gen CHD cardiovascular risk test
• PrecisionCHD diagnostic and management test
• AI-driven DNA biomarker testing platform
• Clinical testing services for cardiovascular disease
• Channel-partner and employer testing programs

- **Cardiovascular diagnostic tests** (100%) — Commercial blood- and DNA-based tests used to assess coronary heart disease risk and support diagnosis/management.
- **Testing platform and clinical workflow** (0%) — The underlying AI-driven biomarker technology and lab-enabled workflow used to deliver the tests.

- Epi+Gen CHD cardiovascular risk test
- PrecisionCHD diagnostic and management test
- AI-driven DNA biomarker testing platform
- Clinical testing services for cardiovascular disease
- Channel-partner and employer testing programs

## Customers

Cardio sells primarily to provider organizations that order tests for patients and use the results in clinical decision-making. The company also serves employers and channel partners that use the tests in screening, prevention, or wellness-oriented programs. Its tests can be paid for by provider organizations, patients, and/or employers, which means buying decisions depend on clinical utility, pricing, and whether the customer can drive sufficient test volume. The company has also referenced expansion through community and partner organizations, indicating a mix of direct clinical and partnership-led demand generation.

- **Provider organizations** (primary) — Clinics and medical groups order Epi+Gen CHD and PrecisionCHD to assess cardiovascular risk and support diagnosis/management.
- **Employers** (secondary) — Employers buy testing for prevention and health-screening programs, often through minimum-volume arrangements.
- **Channel partners** (secondary) — Partners help distribute the tests and expand access into new verticals and local markets.
- **Patients** (emerging) — Patients may pay directly when the test is not fully covered or when it is offered through a provider program.

- Provider organizations buying tests for patient care and risk assessment
- Employers purchasing testing for prevention and workforce health programs
- Channel partners that distribute or bundle the tests into programs
- Patients who may pay directly when coverage is limited
- Community and wellness organizations using tests for outreach initiatives

## Geography

Cardio is headquartered in the United States and its business is still primarily domestic. The company stated that it is expanding into additional markets domestically and internationally, with first international expansion into India. Because the business depends on provider onboarding and local commercial relationships, geography matters more as a go-to-market execution issue than as a manufacturing footprint issue. The company also referenced partnerships with U.S.-based organizations such as YMCA affiliates, showing that market development is still early and relationship-driven.

- **United States** (100%) — Company is U.S.-based and disclosures emphasize domestic commercialization.

- United States is the core market and headquarters location
- India is the first disclosed international expansion market
- Domestic growth depends on onboarding provider organizations
- Community and wellness partnerships support U.S. market access
- No manufacturing footprint was disclosed; operations are service/lab based

## Strategy

Cardio’s strategy is to drive adoption of its clinical solutions among providers, channel partners, and employers. The company is trying to build a broader sales and partnership pipeline while expanding into new vertical markets, which is important because its tests require time to ramp after onboarding. It is also investing in a CLIA-compliant high-complexity laboratory capability, which supports clinical credibility and operational control. International expansion, starting with India, suggests a longer-term effort to broaden the addressable market beyond the initial U.S. base.

- **Provider adoption and test utilization ramp** (short-term) — Revenue depends on onboarding organizations and then increasing test volume over the following quarters.
- **Partnership-led commercialization** (medium-term) — Channel partners and employers can broaden access without relying only on direct sales.
- **Geographic expansion** (medium-term) — New markets can diversify demand and reduce dependence on a small number of U.S. initiatives.
- **Clinical and operational credibility** (short-term) — A CLIA-compliant high-complexity lab supports regulated clinical testing and customer confidence.

- Increase adoption of Epi+Gen CHD and PrecisionCHD among providers
- Expand channel-partner and employer relationships to widen distribution
- Build a more robust sales and partnership pipeline
- Enter new domestic and international markets, including India
- Operate a CLIA-compliant high-complexity laboratory to support clinical testing
- Use community and wellness partnerships to create test demand

## Risks

Cardio is an early-stage diagnostic company with limited operating history and no significant revenue base, so execution risk is high. Its commercialization depends on convincing providers, employers, and partners that its tests offer better value than established serum lipid, proteomic, and imaging alternatives that already have reimbursement pathways and scientific support. The company also faces long sales and partnership cycles, customer onboarding delays, and the risk that new verticals may not generate enough volume to offset marketing spend. As a diagnostic business handling protected health information, it also faces cybersecurity, data privacy, regulatory, and CLIA compliance risks, while broader healthcare consolidation and reimbursement pressure can slow adoption.

- **Limited operating history and early-stage revenue base** [high] — The company has not yet generated significant revenue from product sales and has incurred losses since inception.
- **Intense competition from established diagnostic modalities** [high] — Serum lipid, proteomic, and imaging-based tests have larger market share, more resources, and established reimbursement strategies.
- **Slow provider onboarding and long sales cycles** [medium] — Management disclosed partnership and sales cycles as long as 24 months and a one- to three-quarter ramp after onboarding.
- **Cybersecurity and PHI protection** [medium] — The company relies on third parties for storage and transmission of customer and patient data.
- **Regulatory and laboratory compliance** [high] — Clinical testing depends on CLIA-compliant operations and adherence to licensing obligations.

- Limited operating history and early-stage commercialization
- Intense competition from established cardiovascular diagnostic modalities
- Long sales and partnership cycles that delay revenue ramp
- Customer onboarding can take one to three quarters before usage scales
- Reimbursement and clinical acceptance risk versus entrenched alternatives
- Cybersecurity and protected health information handling risk
- Regulatory and CLIA compliance risk for laboratory operations
- Healthcare consolidation and pricing pressure can reduce adoption

## Accounting

Cardio’s revenue recognition is highly sensitive to test volume, customer mix, and the timing of onboarding, because customers are charged based on minimum committed test volumes and pricing varies by organization type, size, and volume. Quarterly results can be volatile because new provider organizations may take one to three quarters to ramp usage, and the company has already disclosed revenue declines when a specific testing initiative ended. The company also has judgment-heavy accounting around stock-based compensation, which affected general and administrative expense in prior periods, and around estimates and assumptions used in preparing its financial statements. In addition, the exclusive license agreement tied to its core technology creates accounting and disclosure sensitivity around intangible rights, contract compliance, and the risk of termination if obligations are not met.

- **Revenue recognition for test services** — Can create quarter-to-quarter volatility and affect comparability
- **Stock-based compensation** — Can materially affect operating loss and non-cash expense trends
- **Estimates and judgments** — Reported results may differ materially from future outcomes
- **License agreement and intangible rights** — Could affect access to the underlying technology and going-concern analysis

- Revenue recognition depends on test volume and customer-specific pricing
- Quarterly revenue can swing when onboarding ramps slowly or programs end
- Stock-based compensation can materially affect SG&A and reported losses
- Estimates and judgments affect assets, liabilities, revenue, and expenses
- License agreement compliance may affect access to core technology rights
- Clinical testing businesses often face accrual and collectability judgment

---

*Last updated: 2026-04-28T14:25:46.654483+00:00*